Sydney Jennings

Articles

Osteoporosis Screening Misses Younger Postmenopausal Women: Daily Dose

April 02, 2025

Your daily dose of the clinical news you may have missed.

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

April 01, 2025

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Expert Insights: Q&A with Mark Ebell, MD, on Gepotidacin and UTI Management

April 01, 2025

Family physician and researcher Mark Ebell, MD, discusses the clinical implications, efficacy, and role of gepotidacin in UTI management.

Uneven US Cancer Screening Recovery Post-COVID: Daily Dose

April 01, 2025

Your daily dose of the clinical news you may have missed.

FDA Authorizes Marketing of First At-Home Test for Chlamydia, Gonorrhea, Trichomoniasis

March 31, 2025

The Women’s Sexual Health Test (Visby Medical) delivers results in approximately 30 minutes using a vaginal swab.

CagriSema Achieves Significant Weight Loss in Phase 3 Trial: Daily Dose

March 31, 2025

Your daily dose of the clinical news you may have missed.

New Study Suggests Bacterial Vaginosis May be Sexually Transmitted

March 28, 2025

New research shows that treating both men and women with topical and oral antibiotics lowers the odds of bacterial vaginosis recurrence by more than half.

Cleveland Clinic Researchers Develop Risk-Prediction Model for Early-Onset Colorectal Cancer in Young Adults

March 28, 2025

The model identified BMI, tobacco use, and family history of CRC as the strongest predictors for advanced neoplasia in young adults.

Omalizumab Beats OIT in First Head-to-Head Multi-Food Allergy Trial: Daily Dose

March 28, 2025

Your daily dose of the clinical news you may have missed.

April Issue of Patient Care Digital Edition is Now Live

March 27, 2025

The April issue covers atopic dermatitis, highlighting primary care’s role in early diagnosis, key updates from recent conferences, and more.